Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Net Margin of 136.03% for Q1 2026, down 2740.0% year-over-year from 5.15% in Q1 2025, and down 119.33% on a QoQ basis from 62.02% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 11 years of Net Margin data on file, last reported at 136.03% in Q1 2026.
- Quarterly Net Margin fell 2740.0% year-over-year to 136.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.92% (down 9307.0% YoY) and the FY2025 annual result came in at 85.44%, down 8419.0% from the prior year.
- Net Margin slipped to 136.03% in Q1 2026 per RARE's latest filing, from 62.02% in the prior quarter.
- Across five years, Net Margin topped out at 260.43% in Q4 2024 and bottomed at 270.23% in Q3 2022.
- The 5-year median for Net Margin is 136.03% (2026), against an average of 113.36%.
- The widest annual swing landed in 2024, when Net Margin jumped 35761 bps; it then plunged 32246 bps in 2025.
- Tracing RARE's Net Margin over 5 years: stood at 148.5% in 2022, then surged by 35 bps to 97.17% in 2023, then surged by 368 bps to 260.43% in 2024, then plunged by 124 bps to 62.02% in 2025, then tumbled by 119 bps to 136.03% in 2026.
- Per Business Quant, the three latest RARE Net Margin figures stand at 136.03% (Q1 2026), 62.02% (Q4 2025), and 112.81% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -136.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -136.03% |
| Dec 31, 2025 | -62.02% |
| Sep 30, 2025 | -112.81% |
| Jun 30, 2025 | -69.04% |
| Mar 31, 2025 | -108.63% |
| Dec 31, 2024 | 260.43% |
| Sep 30, 2024 | -95.71% |
| Jun 30, 2024 | -89.51% |
| Mar 31, 2024 | -156.83% |
| Dec 31, 2023 | -97.17% |
| Sep 30, 2023 | -162.82% |
| Jun 30, 2023 | -147.57% |
| Mar 31, 2023 | -163.16% |
| Dec 31, 2022 | -148.50% |
| Sep 30, 2022 | -270.23% |
| Jun 30, 2022 | -177.03% |
| Mar 31, 2022 | -190.55% |
| Dec 31, 2021 | -149.65% |
| Sep 30, 2021 | -89.41% |
| Jun 30, 2021 | -140.76% |
| Mar 31, 2021 | -136.97% |
| Dec 31, 2020 | -26.23% |
| Sep 30, 2020 | -84.50% |
| Jun 30, 2020 | 41.02% |
| Mar 31, 2020 | -327.81% |
| Dec 31, 2019 | -263.55% |
| Sep 30, 2019 | -437.96% |
| Jun 30, 2019 | -410.67% |
| Mar 31, 2019 | -532.45% |
| Dec 31, 2018 | -540.10% |
| Sep 30, 2018 | -742.24% |
| Jun 30, 2018 | -412.13% |
| Mar 31, 2018 | 283.35% |
| Dec 31, 2017 | -4,665.57% |
| Sep 30, 2017 | -40,013.64% |
| Dec 31, 2016 | -1,425,040.00% |
| Sep 30, 2016 | -58,474.77% |
| Jun 30, 2016 | -334,841.18% |